David Risinger
Stock Analyst at Leerink Partners
(4.50)
# 223
Out of 5,182 analysts
180
Total ratings
64.65%
Success rate
14.76%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Market Perform | $36 → $40 | $39.76 | +0.60% | 3 | Apr 1, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Outperform | $58 → $86 | $63.60 | +35.22% | 3 | Mar 16, 2026 | |
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $355.60 | -0.17% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $59.47 | +0.89% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $446.78 | +17.51% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $28.48 | +12.36% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $36.76 | +22.42% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $955.19 | +15.58% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $4.80 | +525.00% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $67.08 | +4.35% | 4 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $169 → $153 | $241.31 | -36.60% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $762 → $834 | $767.85 | +8.61% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $212.40 | -3.01% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $31.09 | +121.94% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $14.96 | +6.95% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $61.69 | +148.01% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $16.55 | -39.58% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $68.54 | -31.43% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $142.09 | -35.96% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.22 | +76.34% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $6.91 | +435.46% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $198.14 | -11.17% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $13.61 | +17.56% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $10.60 | +324.53% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.39 | +549.35% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $23.46 | +74.77% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $119.99 | +45.01% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $48.30 | +5.59% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $30.96 | -74.16% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $122.68 | -27.45% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.80 | -76.56% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $34.92 | -54.18% | 9 | Apr 2, 2020 |
Centessa Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: $36 → $40
Current: $39.76
Upside: +0.60%
Oruka Therapeutics
Mar 16, 2026
Maintains: Outperform
Price Target: $58 → $86
Current: $63.60
Upside: +35.22%
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $355.60
Upside: -0.17%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $59.47
Upside: +0.89%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $446.78
Upside: +17.51%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $28.48
Upside: +12.36%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $36.76
Upside: +22.42%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $955.19
Upside: +15.58%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $4.80
Upside: +525.00%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $67.08
Upside: +4.35%
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $241.31
Upside: -36.60%
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $767.85
Upside: +8.61%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $212.40
Upside: -3.01%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $31.09
Upside: +121.94%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $14.96
Upside: +6.95%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $61.69
Upside: +148.01%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $16.55
Upside: -39.58%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $68.54
Upside: -31.43%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $142.09
Upside: -35.96%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.22
Upside: +76.34%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $6.91
Upside: +435.46%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $198.14
Upside: -11.17%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $13.61
Upside: +17.56%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $10.60
Upside: +324.53%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.39
Upside: +549.35%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $23.46
Upside: +74.77%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $119.99
Upside: +45.01%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $48.30
Upside: +5.59%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $30.96
Upside: -74.16%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $122.68
Upside: -27.45%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.80
Upside: -76.56%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $34.92
Upside: -54.18%